B. Riley Expects Lower Earnings for Perspective Therapeutics

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) – Analysts at B. Riley dropped their FY2025 earnings per share (EPS) estimates for Perspective Therapeutics in a research note issued to investors on Monday, November 17th. B. Riley analyst Y. Zhi now forecasts that the company will post earnings per share of ($1.27) for the year, down from their prior estimate of ($1.21). B. Riley currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. B. Riley also issued estimates for Perspective Therapeutics’ Q4 2025 earnings at ($0.37) EPS.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.02). The company had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.21 million. Perspective Therapeutics had a negative return on equity of 33.37% and a negative net margin of 7,688.50%.

A number of other research analysts have also commented on the company. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, November 11th. UBS Group reaffirmed a “buy” rating and set a $7.00 price target on shares of Perspective Therapeutics in a research note on Friday. BTIG Research began coverage on Perspective Therapeutics in a research report on Friday, October 10th. They issued a “buy” rating and a $14.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Perspective Therapeutics in a report on Friday, October 3rd. Four investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Perspective Therapeutics presently has a consensus rating of “Buy” and an average target price of $11.30.

Perspective Therapeutics Price Performance

Shares of NYSEAMERICAN CATX opened at $2.12 on Thursday. The company has a quick ratio of 15.09, a current ratio of 15.09 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average of $3.15 and a two-hundred day moving average of $3.30. Perspective Therapeutics has a 1-year low of $1.60 and a 1-year high of $5.39.

Hedge Funds Weigh In On Perspective Therapeutics

Several institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Perspective Therapeutics by 5.0% in the 3rd quarter. Vanguard Group Inc. now owns 3,437,865 shares of the company’s stock valued at $11,792,000 after acquiring an additional 163,532 shares during the last quarter. Affinity Asset Advisors LLC increased its stake in Perspective Therapeutics by 71.1% in the first quarter. Affinity Asset Advisors LLC now owns 2,224,196 shares of the company’s stock valued at $4,738,000 after purchasing an additional 924,196 shares in the last quarter. Nicholson Wealth Management Group LLC raised its holdings in Perspective Therapeutics by 0.3% in the second quarter. Nicholson Wealth Management Group LLC now owns 1,614,283 shares of the company’s stock worth $5,553,000 after purchasing an additional 5,000 shares during the period. Geode Capital Management LLC raised its holdings in Perspective Therapeutics by 15.8% in the second quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock worth $4,758,000 after purchasing an additional 188,887 shares during the period. Finally, Nuveen LLC bought a new position in shares of Perspective Therapeutics during the first quarter worth $2,647,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.